Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Solid Biosciences Are Jumping Today

By Jason Hawthorne – Sep 21, 2021 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shareholders are expecting to finally get good news.

What happened

Shares of Solid Biosciences (SLDB -0.89%) are up 24% as of 11:15 a.m. EDT as the company prepares to present long-term data for three patients in a phase 1/2 study of its treatment for Duchenne muscular dystrophy. The presentation will take place at the World Muscle Society Virtual Congress.  

A family outside of their front door.

Image source: Getty Images.

So what

Solid's drug candidate -- SGT-001 -- is a gene transfer therapy designed to address the absence of the dystrophin protein in those with the disease. Early data suggests SGT-001 could slow or stop the progression of Duchenne muscular dystrophy regardless of how far the disease has progressed.

The market for treatments is estimated to be slightly less than $1 billion, but it is growing more than 40% per year. To date, only one drug has been approved by the Food and Drug Administration (FDA) to treat Duchenne. That's a weekly hourlong infusion created by a subsidiary of a Japanese pharmaceutical company. Notably, that treatment from is a piece of synthetic messenger RNA. That's the same method both Moderna and BioNTech used to create their COVID-19 vaccines.

Now what

Shareholders will eagerly await the data on the three high-dose patients. In 2018, the drug was put on clinical hold by the FDA. Another hold was placed in 2019 when the agency determined a trial participant had suffered a kidney injury associated with SGT-001. In May, Solid shared yet another safety event during its first-quarter earnings call. 

Despite the concerns, Ultragenyx Pharmaceutical (RARE 3.27%) established a partnership with Solid last October. The deal gave Ultragenyx an exclusive license to certain products in exchange for a $40 million investment. It could be worth $255 million based on milestone payments. If the data today is positive, it should give the company negotiating leverage for any potential buyout. It might also give it a leg up in the race for a treatment. Sarepta Therapeutics (SRPT -0.15%) and Pfizer (PFE 0.74%) have Duchenne programs of their own. 

Jason Hawthorne owns shares of BioNTech SE. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Solid Biosciences Inc. Stock Quote
Solid Biosciences Inc.
SLDB
$6.67 (-0.89%) $0.06
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Sarepta Therapeutics Stock Quote
Sarepta Therapeutics
SRPT
$114.57 (-0.15%) $0.17
Ultragenyx Pharmaceutical Stock Quote
Ultragenyx Pharmaceutical
RARE
$35.72 (3.27%) $1.13
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
360%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.